|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1700 K Street, NW |
Address2 | Suite 740 |
City | Washington |
State | DC |
Zip Code | 20006 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 401010854-12
|
||||||||
|
6. House ID# 421710000
|
TYPE OF REPORT | 8. Year | 2021 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Ryne Carney |
Date | 7/20/2021 3:11:44 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Signed a Protecting Access to Pain Relief (PAPR) Coalition letter urging HHS to explore and support new efforts and support new efforts to promote the work and recommendations of the HHS Pain Management Best Practices Inter-Agency Task Force.
Signed letter in support of H.R. 8920, the Pioneering Antimicrobial Subscriptions to End Up surging Resistance (PASTEUR) Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ryne |
Carney |
|
Intern Rep. Ed Perlmutter |
|
Michael |
Ward |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Signed Ad Hoc Group for Medical Research letter urging investments in medical research be included in any future legislative package focused on bolstering infrastructure. Further, the letter recommended that Congress pass the RISE Act (H.R. 869/S.289)
Signed letter supporting the continued use of human fetal tissue in federal biomedical research
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ryne |
Carney |
|
Intern. Rep. Ed Perlmutter |
|
Michael |
Ward |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Signed a letter in support of the CONNECT for Health Act 2021 (S.1512)
Signed a letter in support of the Comprehensive Care for Alzheimers Act (S. 1125/H.R. 2517)
Signed a letter from the Medical Imaging and Technology Alliance (MITA) urging the Coverage and Analysis Group within CMS to open the pending reconsideration request for amyloid Positron Emission Tomography (PET) scans.
Signed letter urging the House of Representatives and the Senate to create an out-of-pocket cap in Medicare Part D, reform the Part D exceptions and appeals process, bolster the low-income subsidy program, eliminate cost-sharing for Part D vaccines, and improve information and consumer education for Part D beneficiaries.
Signed a letter as part of the Psychoactive Appropriate Use for Safety and Effectiveness (Project PAUSE) urging CMS to revise the measures of inappropriate use of antipsychotics in skilled nursing facilities and enhance the documentation to support CMSs ability to assess and investigate inappropriate prescribing practices
Submitted letter to Congressional leadership urging an annual out-of-pocket cap in Part D; expansion of low-income subsidy eligibility; placing an inflationary cap in Part D; a requirement that Part D plans share a portion of sales of rebates with beneficiaries at the point of sale; strengthen the Part D appeals process; expand Medicare coverage for dental, vision, and hearing services; and not include the quality-adjusted life year metric in any drug pricing legislation.
Sent letter to House of Representatives leadership urging them not to include International Reference Pricing and Quality-Adjust Life Year metrics in drug pricing legislation.
Met virtually with the House of Representatives and Senate to discuss creating an annual out-of-pocket cap in Medicare Part D, creating a smoothing proposal, and warning against the use of quality-adjusted life-year metrics to determine drug value.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ryne |
Carney |
|
Intern Rep. Ed Perlmutter |
|
Michael |
Ward |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Submitted letter to the Senate Appropriations Subcommittee on Military Construction, Veterans Affairs, and Related Agencies to support at least $902 million in the Fiscal Year (F.Y.) 2022 appropriation for the Department of Veterans Affairs (V.A.) Medical and Prosthetic Research program.
Signed letter to House and Senate appropriations subcommittees urging a $289 million increase for National Institutes of Health (NIH) research on Alzheimers disease and other forms of dementia to accelerate progress as articulated in the Bypass Budget Proposal for FY22; a $500 million increase for aging research across the NIH, in addition to the funding for dementia-specific research, to ensure that the NIH has the resources to address the many other age-related chronic diseases that affect people with dementia; a $3.2 billion increase for the NIHs current institutes and operations, including funds from the 21st Century Cures Act for targeted initiatives; $6.5 billion to launch the Advanced Research Projects Agency for Health (ARPA-H); $560 million for the BRAIN Initiative; $200 million for the FDA, in addition to funds included in the 21st Century Cures Act for targeted initiatives double funding for Older Americans Act programs and services; a $7.5 million increase for the ACL Alzheimers Disease Program; an $8.263 million increase for the HRSA geriatrics workforce programs; a $2 million increase for the DoJ Missing Alzheimers Disease Alert Program; $60 million for the CDCs Alzheimers Disease and Healthy Aging Program (ADHAP) to continue BOLD Act implementation, expand the CDC Healthy Brain Initiative road map for state and national partnerships, and reduce dementia risk through brain health promotion; and a $500 million increase for the Federally Qualified Health Centers (FQHCs).
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ryne |
Carney |
|
Intern, Rep. Ed Perlmutter |
|
Michael |
Ward |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |